Effects of intravenous and oral magnesium on reducing migraine: A meta-analysis of randomized controlled trials

Hsiao-Yean Chiu, Tu Hsueh Yeh, Yin Cheng Huang, Pin Yuan Chen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Migraine attack has been associated with magnesium deficiency. Previous studies investigating the effect of intravenous and oral magnesium on acute migraine attacks and the prevention of migraine have produced equivocal findings. Objective: To evaluate the effects of intravenous magnesium on acute migraine attacks and oral magnesium supplements on migraine prophylaxis. Study Design: A meta-analysis of randomized controlled trials (RCTs). Setting: Electronic databases, namely EMBASE, PubMed, the Wanfang Data Chinese Database, and the China Knowledge Resource Integrated Database were searched from inception to February 24, 2015. Methods: This review was conducted according to the guidelines of the PRISMA. Only RCTs evaluating the effects of intravenous or oral magnesium on migraine compared with a control group were included. Results: A total of 21 studies were included. Of which, 11 studies investigated the effects of intravenous magnesium on acute migraine (948 participants) and 10 examined the effects of oral magnesium on migraine prophylaxis (789 participants). Intravenous magnesium significantly relieved acute migraine within 15 – 45 minutes, 120 minutes, and 24 hours after the initial infusion (Odd ratios [ORs] = 0.23, 0.20, and 0.25, respectively). Oral magnesium significantly alleviated the frequency and intensity of migraine (ORs = 0.20 and 0.27). Limitations: Some of the included studies did not adopt adequate randomization methods. Conclusions: Intravenous magnesium reduces acute migraine attacks within 15 – 45 minutes, 120 minuts, and 24 hours after the initial infusion and oral magnesium alleviates the frequency and intensity of migraine. Intravenous and oral magnesium should be adapted as parts of multimodal approach to reduce migraine.

Original languageEnglish
Pages (from-to)E97-E112
JournalPain Physician
Volume19
Issue number1
Publication statusPublished - 2016

Fingerprint

Migraine Disorders
Magnesium
Meta-Analysis
Randomized Controlled Trials
Databases
Odds Ratio
Magnesium Deficiency
Random Allocation
PubMed
China
Guidelines

Keywords

  • Magnesium
  • Meta-analysis
  • Migraine

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Effects of intravenous and oral magnesium on reducing migraine : A meta-analysis of randomized controlled trials. / Chiu, Hsiao-Yean; Yeh, Tu Hsueh; Huang, Yin Cheng; Chen, Pin Yuan.

In: Pain Physician, Vol. 19, No. 1, 2016, p. E97-E112.

Research output: Contribution to journalArticle

@article{143cd429f8f648a5b51f9f04e74d6dc2,
title = "Effects of intravenous and oral magnesium on reducing migraine: A meta-analysis of randomized controlled trials",
abstract = "Background: Migraine attack has been associated with magnesium deficiency. Previous studies investigating the effect of intravenous and oral magnesium on acute migraine attacks and the prevention of migraine have produced equivocal findings. Objective: To evaluate the effects of intravenous magnesium on acute migraine attacks and oral magnesium supplements on migraine prophylaxis. Study Design: A meta-analysis of randomized controlled trials (RCTs). Setting: Electronic databases, namely EMBASE, PubMed, the Wanfang Data Chinese Database, and the China Knowledge Resource Integrated Database were searched from inception to February 24, 2015. Methods: This review was conducted according to the guidelines of the PRISMA. Only RCTs evaluating the effects of intravenous or oral magnesium on migraine compared with a control group were included. Results: A total of 21 studies were included. Of which, 11 studies investigated the effects of intravenous magnesium on acute migraine (948 participants) and 10 examined the effects of oral magnesium on migraine prophylaxis (789 participants). Intravenous magnesium significantly relieved acute migraine within 15 – 45 minutes, 120 minutes, and 24 hours after the initial infusion (Odd ratios [ORs] = 0.23, 0.20, and 0.25, respectively). Oral magnesium significantly alleviated the frequency and intensity of migraine (ORs = 0.20 and 0.27). Limitations: Some of the included studies did not adopt adequate randomization methods. Conclusions: Intravenous magnesium reduces acute migraine attacks within 15 – 45 minutes, 120 minuts, and 24 hours after the initial infusion and oral magnesium alleviates the frequency and intensity of migraine. Intravenous and oral magnesium should be adapted as parts of multimodal approach to reduce migraine.",
keywords = "Magnesium, Meta-analysis, Migraine",
author = "Hsiao-Yean Chiu and Yeh, {Tu Hsueh} and Huang, {Yin Cheng} and Chen, {Pin Yuan}",
year = "2016",
language = "English",
volume = "19",
pages = "E97--E112",
journal = "Pain Physician",
issn = "1533-3159",
publisher = "Association of Pain Management Anesthesiologists",
number = "1",

}

TY - JOUR

T1 - Effects of intravenous and oral magnesium on reducing migraine

T2 - A meta-analysis of randomized controlled trials

AU - Chiu, Hsiao-Yean

AU - Yeh, Tu Hsueh

AU - Huang, Yin Cheng

AU - Chen, Pin Yuan

PY - 2016

Y1 - 2016

N2 - Background: Migraine attack has been associated with magnesium deficiency. Previous studies investigating the effect of intravenous and oral magnesium on acute migraine attacks and the prevention of migraine have produced equivocal findings. Objective: To evaluate the effects of intravenous magnesium on acute migraine attacks and oral magnesium supplements on migraine prophylaxis. Study Design: A meta-analysis of randomized controlled trials (RCTs). Setting: Electronic databases, namely EMBASE, PubMed, the Wanfang Data Chinese Database, and the China Knowledge Resource Integrated Database were searched from inception to February 24, 2015. Methods: This review was conducted according to the guidelines of the PRISMA. Only RCTs evaluating the effects of intravenous or oral magnesium on migraine compared with a control group were included. Results: A total of 21 studies were included. Of which, 11 studies investigated the effects of intravenous magnesium on acute migraine (948 participants) and 10 examined the effects of oral magnesium on migraine prophylaxis (789 participants). Intravenous magnesium significantly relieved acute migraine within 15 – 45 minutes, 120 minutes, and 24 hours after the initial infusion (Odd ratios [ORs] = 0.23, 0.20, and 0.25, respectively). Oral magnesium significantly alleviated the frequency and intensity of migraine (ORs = 0.20 and 0.27). Limitations: Some of the included studies did not adopt adequate randomization methods. Conclusions: Intravenous magnesium reduces acute migraine attacks within 15 – 45 minutes, 120 minuts, and 24 hours after the initial infusion and oral magnesium alleviates the frequency and intensity of migraine. Intravenous and oral magnesium should be adapted as parts of multimodal approach to reduce migraine.

AB - Background: Migraine attack has been associated with magnesium deficiency. Previous studies investigating the effect of intravenous and oral magnesium on acute migraine attacks and the prevention of migraine have produced equivocal findings. Objective: To evaluate the effects of intravenous magnesium on acute migraine attacks and oral magnesium supplements on migraine prophylaxis. Study Design: A meta-analysis of randomized controlled trials (RCTs). Setting: Electronic databases, namely EMBASE, PubMed, the Wanfang Data Chinese Database, and the China Knowledge Resource Integrated Database were searched from inception to February 24, 2015. Methods: This review was conducted according to the guidelines of the PRISMA. Only RCTs evaluating the effects of intravenous or oral magnesium on migraine compared with a control group were included. Results: A total of 21 studies were included. Of which, 11 studies investigated the effects of intravenous magnesium on acute migraine (948 participants) and 10 examined the effects of oral magnesium on migraine prophylaxis (789 participants). Intravenous magnesium significantly relieved acute migraine within 15 – 45 minutes, 120 minutes, and 24 hours after the initial infusion (Odd ratios [ORs] = 0.23, 0.20, and 0.25, respectively). Oral magnesium significantly alleviated the frequency and intensity of migraine (ORs = 0.20 and 0.27). Limitations: Some of the included studies did not adopt adequate randomization methods. Conclusions: Intravenous magnesium reduces acute migraine attacks within 15 – 45 minutes, 120 minuts, and 24 hours after the initial infusion and oral magnesium alleviates the frequency and intensity of migraine. Intravenous and oral magnesium should be adapted as parts of multimodal approach to reduce migraine.

KW - Magnesium

KW - Meta-analysis

KW - Migraine

UR - http://www.scopus.com/inward/record.url?scp=84954423859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954423859&partnerID=8YFLogxK

M3 - Article

C2 - 26752497

AN - SCOPUS:84954423859

VL - 19

SP - E97-E112

JO - Pain Physician

JF - Pain Physician

SN - 1533-3159

IS - 1

ER -